The effect of clozapine on immune-related biomarkers in schizophrenia patients

IF 3.5 3区医学 Q2 NEUROSCIENCES Brain Research Bulletin Pub Date : 2024-11-01 DOI:10.1016/j.brainresbull.2024.111104

Lu Shao, Yu Li, ZhiYao Yuan, XiYu Guo, GuoJi Zeng, JunPeng Liu

{"title":"The effect of clozapine on immune-related biomarkers in schizophrenia patients","authors":"Lu Shao, Yu Li, ZhiYao Yuan, XiYu Guo, GuoJi Zeng, JunPeng Liu","doi":"10.1016/j.brainresbull.2024.111104","DOIUrl":null,"url":null,"abstract":"<div><div>Globally, schizophrenia is one of the main causes of disability. Approximately 1 % of the general population suffers from schizophrenia, and 30 % of cases are unresponsive to therapy. Clozapine is the gold standard for therapy-resistant schizophrenia (TRS), yet it has limited effectiveness and serious adverse events in some patients. Because of the possibility of severe neutropenia, clozapine administration requires monthly hematological monitoring in the first four months. Previous investigations have demonstrated the immune system alteration after clozapine treatment in schizophrenia patients. Besides, it has been proposed that clozapine changes the cytokines profile in schizophrenia patients. These findings highlighted the need to learn more about the disease's etiology and investigate the relationship between peripheral immune system markers and clozapine response to support strategies for better treatment outcomes. The time decision-making to start clozapine could be significantly decreased if some biomarkers were developed to assist physicians in anticipating whether a particular patient will respond to the medication. Therefore, this study aimed to comprehensively review the effect of clozapine on immune-related biomarkers in schizophrenia patients.</div></div>","PeriodicalId":9302,"journal":{"name":"Brain Research Bulletin","volume":"218 ","pages":"Article 111104"},"PeriodicalIF":3.5000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brain Research Bulletin","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0361923024002387","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Globally, schizophrenia is one of the main causes of disability. Approximately 1 % of the general population suffers from schizophrenia, and 30 % of cases are unresponsive to therapy. Clozapine is the gold standard for therapy-resistant schizophrenia (TRS), yet it has limited effectiveness and serious adverse events in some patients. Because of the possibility of severe neutropenia, clozapine administration requires monthly hematological monitoring in the first four months. Previous investigations have demonstrated the immune system alteration after clozapine treatment in schizophrenia patients. Besides, it has been proposed that clozapine changes the cytokines profile in schizophrenia patients. These findings highlighted the need to learn more about the disease's etiology and investigate the relationship between peripheral immune system markers and clozapine response to support strategies for better treatment outcomes. The time decision-making to start clozapine could be significantly decreased if some biomarkers were developed to assist physicians in anticipating whether a particular patient will respond to the medication. Therefore, this study aimed to comprehensively review the effect of clozapine on immune-related biomarkers in schizophrenia patients.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

氯氮平对精神分裂症患者免疫相关生物标志物的影响。

在全球范围内，精神分裂症是导致残疾的主要原因之一。约有 1%的人口患有精神分裂症，其中 30% 的病例对治疗无反应。氯氮平是治疗耐药精神分裂症（TRS）的金标准，但其疗效有限，且在一些患者中会出现严重的不良反应。由于氯氮平可能导致严重的中性粒细胞减少症，因此在使用氯氮平的前四个月，需要每月进行一次血液监测。以往的研究表明，精神分裂症患者接受氯氮平治疗后，免疫系统会发生改变。此外，还有人认为氯氮平改变了精神分裂症患者的细胞因子谱。这些发现突出表明，有必要进一步了解该疾病的病因，并研究外周免疫系统标志物与氯氮平反应之间的关系，以支持改善治疗效果的策略。如果能开发出一些生物标志物来帮助医生预测特定患者是否会对药物产生反应，那么启动氯氮平的决策时间就会大大缩短。因此，本研究旨在全面回顾氯氮平对精神分裂症患者免疫相关生物标志物的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Brain Research Bulletin 医学-神经科学

CiteScore

6.90

自引率

2.60%

发文量

253

审稿时长

67 days

期刊介绍： The Brain Research Bulletin (BRB) aims to publish novel work that advances our knowledge of molecular and cellular mechanisms that underlie neural network properties associated with behavior, cognition and other brain functions during neurodevelopment and in the adult. Although clinical research is out of the Journal''s scope, the BRB also aims to publish translation research that provides insight into biological mechanisms and processes associated with neurodegeneration mechanisms, neurological diseases and neuropsychiatric disorders. The Journal is especially interested in research using novel methodologies, such as optogenetics, multielectrode array recordings and life imaging in wild-type and genetically-modified animal models, with the goal to advance our understanding of how neurons, glia and networks function in vivo.